Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, and Nakanoshima Qross, a unique hub located in Osaka that supports organisations working on innovative new medicines, have signed a memorandum of understanding (MoU).
Nakanoshima Qross provides a home and support for companies, start-ups and researchers that are working on new medicines, such as advanced therapies. It currently hosts 57 organisations, which can access expertise on a range of topics, from understanding current market trends and best practice, to advice on how to commercialise therapies.
CGT Catapult and Nakanoshima Qross will help the continued growth of the advanced therapy sector in Japan and the UK by sharing expertise on new technologies, industry developments and supporting advanced therapy medical research taking place in both countries. They will also assist the organisations they work with to understand and pursue opportunities to collaborate with each other.
The realisation of future medicine requires international collaboration. I sincerely hope that this MoU will serve as a catalyst for greater co-creation and progress among Japan, the United Kingdom, and all relevant stakeholders. The 2025 Osaka-Kansai Expo also presents a valuable opportunity for us to build that future together. I look forward to seeing this agreement become a meaningful first step toward further development.
Dr Yoshiki Sawa, Chairman of Nakanoshima Qross
It is important to work internationally with leading organisations like Nakanoshima Qross to foster stronger connections between the advanced therapies industries in across the world. Japan has a strong heritage of research and innovation, and we look forward to sharing knowledge and encouraging collaboration on this global level.
Matthew Durdy, Chief Executive of the CGT Catapult